The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibody treatments bamlanivimab and Regeneron’s casirivimab/imdevimab for the treatment of mild to moderate COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing. Bamlanivimab and casirivimab/imdevimab are interchangeable.
MedStar Health is pleased to offer Monoclonal Antibody Therapy Infusions at three outpatient locations throughout Maryland and the District of Columbia:
- MedStar Harbor Hospital
3001 S. Hanover Street Baltimore, MD 21225
- MedStar Southern Maryland Hospital Center
10403 Hospital Drive Clinton, MD 20735
- MedStar Washington Hospital Center
106 Irving Street NW, Washington, DC, 20010
Adults: Treatment Eligibility
- Non-hospitalized patients
- Weigh over 40 kilograms
- Mild to moderate COVID-19 symptoms for less than 10 days
- At high risk for progressing to severe COVID-19 and/or hospitalization
Patients with any of the following indicators may benefit from the monoclonal antibody infusion:
- Body mass index (BMI) ≥35
- Chronic kidney disease
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥65 years of age
In addition, patients who are 55 or older who have cardiovascular disease, uncontrolled hypertension, or chronic pulmonary disease may also benefit from treatment.
Pediatrics: Treatment eligibility
Patients who are 12-17 years old and who have any of the following indicators may also benefit
- BMI ≥85th percentile for their age and gender based on CDC growth charts, OR
- Sickle cell disease, OR
- Congenital or acquired heart disease, OR
- Neurodevelopmental disorders, for example, cerebral palsy, OR
- A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control
These therapies are not authorized for use in patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity
- Are pregnant or breastfeeding
- Have an active serious fungal or bacterial infection
- Have planned surgery within the next 7 days or any underlying severe medical condition other than COVID-19 that is deemed life threatening within next 29 days
How to refer a patient
MedStar Health Physicians
- Please use the MedConnect PowerForm (which will automatically pop up in a patient’s chart after a COVID-19 positive test) to properly indicate your patient’s symptom onset, degree of illness, date of COVID-19 testing, and underlying risk factors. A score of 1 or greater indicates your patient meets criteria for treatment. For patients tested outside of MedStar Health who report a positive COVID-19 result, the results of the test can be entered into MedConnect (see job aid here) and the monoclonal scoring form will then pop up as a chart alert for completion.
For Physicians Outside the MedStar Health System
- Complete this infusion center referral form.
The clinical team will review the referral form upon receipt, determine eligibility for the treatment, and contact the patient to coordinate services as soon as possible.
Managing Patient Expectations
Not all COVID-19 positive patients are eligible to receive this treatment. If a patient’s clinical condition changes between the referral and arrival at the infusion center, the patient may no longer be eligible for this treatment. Please discuss this with your patients.